Contributions to the problem of goodness-of-fit

This dissertation consists of two parts. The first part pertains to residual goodness-of-fit analysis. The second part pertains to the possibility of bringing an asymptotic multi-decision point of view to goodness-of-fit analysis;Goodness-of-fit testing based on the Correlated (OLS) residuals for the standard linear regression model are investigated in the first part. A modification of the U-statistic is given and appropriate quantiles are discussed. Three new statistics for testing normality are introduced;Goodness-of-fit is also studied through orthogonally transformed residuals. Test size and power are studied for a new vector of transformed residuals (r*), as well as for Theil\u27s BLUS residuals and comparisons are made with the result obtained for the OLS residuals;In the second part, the sense in which bivariate large deviations are pertinent to the three-decision view of goodness-of-fit is explored. Various approaches are discussed for computing or approximating the large deviation rates for the classification errors involved

Contributions to the problem of goodness-of-fit

This dissertation consists of two parts. The first part pertains to residual goodness-of-fit analysis. The second part pertains to the possibility of bringing an asymptotic multi-decision point of view to goodness-of-fit analysis;Goodness-of-fit testing based on the Correlated (OLS) residuals for the standard linear regression model are investigated in the first part. A modification of the U-statistic is given and appropriate quantiles are discussed. Three new statistics for testing normality are introduced;Goodness-of-fit is also studied through orthogonally transformed residuals. Test size and power are studied for a new vector of transformed residuals (r*), as well as for Theil's BLUS residuals and comparisons are made with the result obtained for the OLS residuals;In the second part, the sense in which bivariate large deviations are pertinent to the three-decision view of goodness-of-fit is explored. Various approaches are discussed for computing or approximating the large deviation rates for the classification errors involved.</p

Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D-CFTR mutation treated with ivacaftor

BACKGROUND: Pulmonary exacerbations (PEx) are associated with acute loss of lung function that is often not recovered after treatment. We investigated lung function recovery following PEx for ivacaftor- and placebo-treated subjects. METHODS: Short- and long-term pulmonary function recovery data after PEx were summarized from a placebo-controlled trial in 161 cystic fibrosis patients≥12years old with the G551D-CFTR mutation (NCT00909532). Short-term recovery was measured 2 to 8weeks after treatment, and long-term recovery was determined at the end-of-study, both compared with baseline measured just prior to the PEx. RESULTS: Fewer patients receiving ivacaftor experienced a PEx than patients receiving placebo (33.7% vs. 56.4%; P=0.004) and had a lower adjusted incidence rate of PEx (0.589 vs. 1.382; P<0.001). The proportion of PEx followed by full short-term recovery of percent predicted forced expiratory volume in 1s was similar (ivacaftor vs. placebo, 57.1% vs. 53.7), as was the proportion of patients having long-term recovery (46.4% vs. 47.7%). CONCLUSIONS: Ivacaftor treatment reduces the frequency of PEx but does not improve on the rate of complete lung function recovery after PEx when compared with placebo

Recovery of lung function following a pulmonary exacerbation in patients with cystic fibrosis and the G551D-CFTR mutation treated with ivacaftor

Background: Pulmonary exacerbations (PEx) are associated with acute loss of lung function that is often not recovered after treatment. We investigated lung function recovery following PEx for ivacaftor- and placebo-treated subjects